Rabies shot under the skin: could it work?
NCT ID NCT01044199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a rabies vaccine (RabAvert) can be given just under the skin instead of into a muscle. Researchers tested it in 130 adults, some who had never been vaccinated and some who had. The goal was to see if the skin shot triggers enough protection and is safe. Results could lead to a simpler vaccination method.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PCEC rabies vaccine (RabAvert)
- What this could lead to
- If successful, this could offer a simpler, less invasive way to protect against rabies, potentially using less vaccine per dose.
- What could go wrong
- This is a completed early-stage study with 130 participants, so results may not apply to everyone. The intradermal method may not be as effective as the standard shot for all people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
130 people
The number who actually took part.
- Start date
-
Feb 2009
- Finished
-
Aug 2013
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Laboratory personnel, epidemiologists, EISOs, veterinary students, interns, and other first responders at CDC; other CDC employees; and healthy volunteer adults. Persons who contact the study coordinator will be assessed for possible occupational exposure to rabies using the risk assessment form (appendix E). The volunteers reporting occupational exposure will be selected to enter the study. 2. Male or nonpregnant females (as indicated by a negative urine pregnancy test prior to first dose of vaccine), aged 18 years and older. 3. Women of childbearing potential who are at risk of becoming pregnant must agree to practice adequate contraception (i.e., barrier method, abstinence, or licensed hormonal methods) for the entire study period. 4. Be in good health, as determined by vital signs (pulse, blood pressure, oral temperature), medical history, and a targeted physical examination based on medical history. 5. Able to understand and comply with planned study procedures. 6. Provide informed consent prior to any study procedures and be available for all study visits. 7. Have health insurance. Exclusion Criteria: 1. Have a known allergy to PCECV. 2. Have a known allergy or sensitivity to eggs or latex (in the stopper). 3. Have a positive urine pregnancy test prior to first vaccine dose (female of childbearing potential age). 4. Are immunosuppressed as a result of an underlying illness or treatment. 5. Have active neoplastic disease or a history of any hematologic malignancy. 6. Are using oral or parenteral steroids, high-dose inhaled steroids (\>800 μg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 7. Have a history of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study. 8. Have an acute illness that is accompanied by an oral temperature greater than 100.4°F, within 1 week of vaccination. 9. Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to enrollment in this study, or expects to receive an experimental agent during the 1st month of the study period. 10. Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. 11. He/she is a CDC worker under direct supervision of any of the primary study investigators (Dr. Sergio Recuenco, and Dr. Eli Warnock).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rabies exposure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CDC Occupational Clinic
Atlanta, Georgia, 30333, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.